Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccinationArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome addition adenoviral-vectored vaccine antibody AZD1222 binding antibody BNT162b2 booster booster vaccination Booster vaccine comparable Complete coronavirus Coronavirus 2019 COVID-19 demonstrated develop dose Effect enrolled enzyme-linked immunosorbent Heterologous highest immune evasion immune response Immunogenicity analysis individual induce interferon-γ Messenger RNA Mild moderate mRNA mRNA vaccine mRNA-1273 mutations NAb titer NAbs neutralization neutralize Neutralizing Neutralizing activity neutralizing antibody observé Omicron variant Omicron. overcome participant raise receive receiving reduction response Serious Adverse Events significant increase Spike protein T-cell activation T-cell Response T-cell responses vaccination Vaccine waning immunity was recorded were measured [DOI] 10.1002/jmv.28044 PMC 바로가기
SARS-CoV-2 RNA load in nasopharyngeal specimens from outpatients with breakthrough COVID-19 due to Omicron BA.1 and BA.2Article Published on 2022-12-012022-11-16 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome All participant BA.1 BA.2 Booster vaccine caused collected comparable composed coronavirus coronavirus disease COVID-19 Day Diagnosis dose elapsed had no Infection log median median age nasopharyngeal specimen omicron Omicron variant Outpatient Patient reached retrospective RNA SARS-CoV-2 SARS-CoV-2 RNA Support symptom onset TaqPath Thermo Fisher Scientific time Transmissibility upper respiratory tract URT vaccination schedule Vaccine vaccine dose Viral load Viral load. viral RNA load was used [DOI] 10.1002/jmv.28079 PMC 바로가기
Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trialClinical Trial Published on 2022-11-302023-07-10 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), [키워드] Booster vaccine CoronaVac COVID-19 inactive. TURKOVAC [DOI] 10.1080/21645515.2022.2122503 PMC 바로가기 [Article Type] Clinical Trial
Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigenArticle Published on 2022-11-012022-11-15 Journal: Bone marrow transplantation [Category] SARS, 진단, [키워드] Antigen Booster vaccine CAR-T dose recipient SARS-CoV-2 [DOI] 10.1038/s41409-022-01795-3 PMC 바로가기
Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivorsArticle Published on 2022-11-012022-11-15 Journal: Clinical immunology (Orlando, Fla.) [Category] SARS, 진단, [키워드] acute respiratory syndrome Antibody titer Beta booster booster vaccination Booster vaccine CD4 CD8 comparable coronavirus COVID-19 Delta dose effective elicit elicited generate healthy individual humoral immune response less MOST naïve neutralization neutralizing antibody omicron robust SARS-CoV-1 SARS-CoV-1 survivors SARS-CoV-2 survivor Survivors T cell response T cell responses T-cell Response T-cell response. WA1 while Wuhan-Hu-1 [DOI] 10.1016/j.clim.2022.109103 PMC 바로가기
Antibody responses and SARS-CoV-2 infection after BNT162b2 mRNA booster vaccination among healthcare workers in JapanArticle Published on 2022-11-012022-11-15 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 진단, [키워드] 95% confidence interval 95%CI adjusted odds ratio age analyzed anti-spike antibody Antibody Response BNT162b2 BNT162b2 mRNA booster vaccination Booster vaccine Cohort Coverage COVID-19 decrease dose Effectiveness eight Factor group groups HCW HCWs Health care worker healthcare worker Increased infection control interquartile range introduced IQR Japan median mRNA vaccine mRNA vaccine. multivariate logistic regression no significant difference not significant positive risk factor SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections subject university vaccination Vaccine waning immunity [DOI] 10.1016/j.jiac.2022.07.010 PMC 바로가기
Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic reviewArticle Published on 2022-11-012022-11-15 Journal: British Journal of Cancer [Category] COVID19(2023년), SARS, 진단, [키워드] access acute respiratory syndrome Affect Antibody Response anticancer association B-cell benefit booster booster dose booster vaccination Booster vaccine Cancer Coronavirus-2 depleting dose doses Efficacy evaluated Evidence haematological malignancies immunological responses include induce Infection malignancies morbidity and mortality organ Patient patients Patients with cancer receive recent risk SARS-CoV-2 SARS-CoV-2 vaccination Seroconversion significantly increased solid cancer systematic narrative review systematic review therapy vaccination [DOI] 10.1038/s41416-022-01951-y PMC 바로가기
Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 VariantsArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% CI appear applied approach Blood booster booster vaccination Booster vaccine Cellulose country COVID COVID-19 pandemic decrease evaluate evaluated heterogeneity immune response Immunity immunological protection increase in indicated individual individual level induce median MONITOR NAb Neutralization antibody Neutralizing Neutralizing antibodies neutralizing antibody omicron Omicron variant pandemic POC point of care point-of-care point-of-care test. population level predominant Protective Rapid regimen reported responses against SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants shown stick switching vaccination variant variants of concern variants of SARS-CoV-2 virus neutralization test VoC VOCs waning immunity wild-type [DOI] 10.1128/spectrum.02257-22 PMC 바로가기
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and WalesArticle Published on 2022-10-152022-11-16 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 변종, [키워드] 95% CI adjusted age analyses Analysis analysis aRR association B.1.1.529 benefit BNT162b2 booster booster dose Booster vaccine calculated ChAdOx1 nCoV-19 Chronic kidney disease Committee Comorbidities Comorbidity conducted core covariates COVID-19 COVID-19 hospitalisation COVID-19 infection COVID-19 therapeutics COVID-19 vaccination current death dominant Edinburgh England event group Health health condition high risk hospitalisation identify immunisation Immunosuppressant increased risk individual initial Innovation Ireland male Medical Research Council meta-analyses Moderna mortality data mRNA-1273 Multimorbidity National of BNT162b2 offer older adult outcome outcomes Oxford-AstraZeneca per 1000 person-year per 1000 person-years Pfizer-BioNTech Poisson regression model primary care prospective cohort prospective cohort study rate ratio receiving reduced reduced risk remained risk risk factor RT-PCR testing SARS-COV-2 infection Scottish severe COVID-19 Sex those with comorbidity university vaccination Vaccine vaccine dose vaccine group variant [DOI] 10.1016/S0140-6736(22)01656-7 PMC 바로가기
A Bivalent Omicron-Containing Booster Vaccine against Covid-19Article Published on 2022-10-062022-11-15 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome addition Administered Alpha B.1.1.529 binding antibody Bivalent booster booster dose Booster vaccine booster vaccines coronavirus dose Effectiveness elicited Exploratory analysis geometric mean titer group Infection Interim median time mRNA-1273 mRNA-1273 booster neutralizing antibody Neutralizing antibody response occurred other variant participant Participants reactogenicity responses against RNAs Safety SARS-CoV-2 SARS-COV-2 infection Vaccine variant Wuhan-Hu-1 [DOI] 10.1056/NEJMoa2208343 PMC 바로가기